GC Cell Initiates First Patient Dosing in Phase 1 Clinical Trial for GCC2005, a Promising T‑Cell Lymphoma CD5 CAR-NK Therapy
YONGIN, South Korea, March 13, 2025 /PRNewswire/ -- GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This...
SKF continues the preparations for the separation of its Automotive business; initiates consent solicitation
GOTHENBURG, Sweden, Feb. 7, 2025 /PRNewswire/ -- In September 2024, SKF announced the decision to initiate a separation of its Automotive business with the objective of a separate listing on Nasdaq Stockholm through a Lex Asea distribution to its...
CARsgen Announces the Initiation of an Investigator-Initiated Trial for an Allogeneic CD19/CD20 CAR-T Therapy
SHANGHAI, Dec. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the initiation of an...
Steelhead LNG Initiates New Legal Proceedings Against Cedar LNG in British Columbia; Receives Three New United States Patents
VANCOUVER, BC, Dec. 24, 2024 /PRNewswire/ -- Steelhead LNG, a Vancouver-based developer in the liquefied natural gas (LNG) industry, today announced the filing of new legal proceedings against Cedar LNG, Pembina Pipeline Corporation and ARC...
ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine
First Implants of Innovative Device Completed in the United States and Australia MINNEAPOLIS, Dec. 3, 2024 /PRNewswire/ -- ShiraTronics, a clinical-stage innovator in neuromodulation technology, today announced the initiation of its U.S. Food and...